Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
2375 results about "Fibrocyte" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
A fibrocyte is an inactive mesenchymal cell, that is, a cell showing minimal cytoplasm, limited amounts of rough endoplasmic reticulum and lacks biochemical evidence of protein synthesis. The term fibrocyte contrasts with the term fibroblast. Fibroblasts are activated connective tissue cells characterized by synthesis of proteins of the fibrous matrix, particularly the collagens. When tissue is injured, the predominant mesenchymal cells, the fibroblast, have been believed to be derived from the fibrocyte or possibly from smooth muscle cells lining vessels and glands. Commonly, fibroblasts express smooth muscle actin, a form of actin first found in smooth muscle cells and not found in resting fibrocytes. Fibroblasts expressing this form of actin are usually called "myo-fibroblasts."
Particulate acellular tissue matrix
A method of processing an acellular tissue matrix to give a particulate acellular tissue matrix includes: cutting sheets of dry acellular tissue matrix into strips; cryofracturing the dry acellular tissue matrix strips at cryogenic temperatures; separating the resulting particles by size at cryogenic temperatures; and freeze drying the fraction of particles desired size to remove any moisture that may have been absorbed to give a dry particulate acellular tissue matrix. Rehydration of the dry particulate acellular tissue matrix may take place just prior to use. The particulate acellular tissue may be applied to a recipient site, by way of injection, spraying, layering, packing, in-casing or combinations thereof. The particulate acellular tissue may further include growth and stimulating agents selected from epidermal growth factor, fibroblast growth factor, nerve growth factor, keratinocyte growth factor, platelet derived growth factor, vasoactive intestinal peptide, stem cell factor, bone morphogetic proteins, chondrocyte growth factor and combinations thereof. Other pharmaceutically active compounds may be combined with the rehydrated particulate material including: analgesic drugs; hemostatic drugs; antibiotic drugs; local anesthetics and the like to enhance the acceptance of the implanted particulate material. The particulate material product may also be combined with stem cells selected from mesenchymal stem cells, epidermal stem cells, cartilage stem cells, hematopoietic stem cells and combinations thereof.
Owner:LIFECELL
Pluripotential embryonic stem cells and methods of making same
The present invention provides a non-mouse, including human, pluripotential embryonic stem cell which can:(a) be maintained on feeder layers for at least 20 passages; and(b) give rise to embryoid bodies and multiple differentiated cell phenotypes in monolayer culture.The invention further provides a method of making a pluripotential embryonic stem cell comprising culturing germ cells and germ cell progenitors in a composition comprising a growth enhancing amount of basic fibroblast growth factor, leukemia inhibitory factor, membrane associated steel factor, and soluble steel factor to primordial germ cells under cell growth conditions, thereby making a pluripotential embryonic stem cell.Also provided are compositions useful to produce the pluripotent embryonic stem cells and methods of screening associated with the method of making the embryonic stem cell.
Owner:VANDERBILT UNIV
Methods for the culture of human embryonic stem cells on human feeder cells
InactiveUS7432104B2Artificial cell constructsMammal material medical ingredientsBone Marrow Stromal CellCell culture media
Methods and cell culture medium for the generation of human pluripotent embryonic stem cells are disclosed. Human embryonic stem cells are cultured with human granulosa feeder cells, muscle cells, Fallopian ductal epithelial cells, bone marrow stromal cells, and skin fibroblasts and the embryonic stem cells maintain their pluripotent phenotype. The human pluripotent embryonic stem cells can be cultured without feeder cells, and in the presence of supplemental growth factors. The human pluripotent embryonic stem cells can be alternatively cultured with conditioned medium obtained from a cell culture capable of maintaining human embryonic stem cells in a pluripotent state, wherein the cell culture is a human granulosa cell culture.
Owner:VIACYTE INC
Muteins of Fibroblast Growth Factor 21
InactiveUS20070293430A1Reduced deamidationReduce capacityPeptide/protein ingredientsMetabolism disorderWild typeNucleic acid sequencing
The present invention relates to novel muteins of human fibroblast growth factor 21 with reduced deamidation compared to wild-type human FGF-21. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, or metabolic syndrome.
Owner:ELI LILLY & CO
Chimeric fibroblast growth factors with altered receptor specificity
ActiveUS20110104152A1Peptide/protein ingredientsAntibody mimetics/scaffoldsDna encodingTherapeutic treatment
The present invention is directed to novel chimeric fibroblast growth factor (FGF) polypeptides, novel DNA encoding chimeric FGF polypeptides, and to the recombinant production of chimeric FGF polypeptides, and to methods, compositions and assays utilizing chimeric FGF polypeptides for the therapeutic treatment of metabolic-related disorders and other conditions, and for producing pharmaceutically active compositions including chimeric FGF polypeptides, the compositions having therapeutic and pharmacologic properties including those associated with the treatment of metabolic-related disorders and other conditions.
Owner:F HOFFMANN LA ROCHE & CO AG
Methods For Treating Wounds
InactiveUS20030125264A1Increasing cell proliferationPromote cell growthBiocideCarbohydrate active ingredientsFibroblastPharmaceutical drug
Pharmaceutical compositions, and methods of using the same, are provided utilizing effective amounts of one or more flavones, flavonols, flavanones, isoflavanones and isoflavones to increase cell proliferation in various tissues and cell lines. As examples, the composition and methods of the present invention can be used to increase proliferation of fibroblast cells and, more particularly, in the treatment of wounds as well as strengthening of the skin.
Owner:KIMBERLY-CLARK WORLDWIDE INC
Fibroblast growth factor-like polypeptides
Owner:AMGEN INC
Remodeling and Glycopegylation of Fibroblast Growth Factor (Fgf)
InactiveUS20080176790A1Improve pharmacokineticsCost effectiveOrganic active ingredientsFungiMutantPolynucleotide
The present invention relates to mutants of Fibroblast Growth Factor (FGF), particularly FGF-20 and FGF-21, which contain newly introduced N-linked or O-linked glycosylation site(s). The polynucleotide coding sequences for the mutants, expression cassettes comprising the coding sequences, cells expressing the mutants, and methods for producing the mutants are also disclosed. Further disclosed are pharmaceutical compositions comprising the mutants and method for using the mutants.
Owner:89BIO LTD +1
Muscle-derived cells (MDCs) for treating muscle- or bone-related injury or dysfunction
The present invention provides muscle-derived cells, preferably myoblasts and muscle-derived stem cells, genetically engineered to contain and express one or more heterologous genes or functional segments of such genes, for delivery of the encoded gene products at or near sites of musculoskeletal, bone, ligament, meniscus, cartilage or genitourinary disease, injury, defect, or dysfunction. Ex vivo myoblast mediated gene delivery of human inducible nitric oxide synthase, and the resulting production of nitric oxide at and around the site of injury, are particularly provided by the invention as a treatment for lower genitourinary tract dysfunctions. Ex vivo gene transfer for the musculoskeletal system includes genes encoding acidic fibroblast growth factor, basic fibroblast growth factor, epidermal growth factor, insulin-like growth factor, platelet derived growth factor, transforming growth factor-β, transforming growth factor-α, nerve growth factor and interleukin-1 receptor antagonist protein (IRAP), bone morphogenetic protein (BMPs), cartilage derived morphogenetic protein (CDMPs), vascular endothelial growth factor (VEGF), and sonic hedgehog proteins.
Owner:UNIVERSITY OF PITTSBURGH
Graft collar and scaffold apparatuses for musculoskeletal tissue engineering and related methods
This application describes apparatuses and methods for musculoskeletal tissue engineering. Specifically, graft collar and scaffold apparatuses are provided for promoting fixation of musculoskeletal soft tissue to bone.This application provides for graft collars comprising biopolymer mesh and / or polymer-fiber mesh for fixing tendon to bone. In one aspect, the graft collar comprises more than one region, wherein the regions can comprise different materials configured to promote integration of and the regeneration of the interfacial region between tendon and bone.This application also provides for scaffold apparatuses and methods for fixing musculoskeletal soft tissue to bone. The scaffold apparatus is multiphasic, preferably triphasic, and each phase is configured promote growth and proliferation of a different cell and its associated tissue. In one aspect, the scaffold apparatus is triphasic, with phases comprising materials to promote growth and proliferation of fibroblasts, chondroblasts, and osteoblasts. In addition, an apparatus comprising two portions, each of said portion being the scaffold apparatus described above is provided, wherein each of said portion encases one end of a soft tissue graft. Further, a triphasic interference screw is provided.This application further provides apparatuses and methods for inducing formation of fibrocartilage comprising wrapping a graft collar with polymer-fiber mesh configured to apply compression to the graft collar. In another aspect, the polymer-fiber is applied directly to the graft to apply compression to the graft.
Owner:THE TRUSTEES OF COLUMBIA UNIV IN THE CITY OF NEW YORK
Compositions and methods for skin care
Compositions and methods are for disclosed for treating a skin condition that results from reactive oxygen species production in skin of a subject, including applying a topical formulation that contains a lipophilic cation-mitochondrially targeted antioxidant compound and that delivers a therapeutically effective amount of the antioxidant compound to skin fibroblasts and keratinocytes.
Owner:ANTIPODEAN PHARMA
Methods and compositions based on inhibition of cell invasion and fibrosis by anionic polymers
Owner:TRIAD
Method of cloning reproductive and respiratory syndrome resisting pig
Owner:CHINA AGRI UNIV
Compositions, uses and methods for treatment of metabolic disorders and diseases
ActiveUS20130023474A1Lower Level RequirementsIncrease insulin sensitivityOrganic active ingredientsFungiDiseaseFGF19
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Chimeric fgf21 proteins with enhanced binding affinity for beta-klotho for the treatment of type ii diabetes, obesity, and related metabolic disorders
The present invention relates to chimeric proteins that include an N-terminus coupled to a C-terminus, where the N-terminus includes an N-terminal portion of fibroblast growth factor 21 (“FGF21”) and the C-terminus includes a C-terminal portion of fibroblast growth factor 19 (“FGF19”). The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, as well as methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, methods of treating a subject in need of increased FGF21-βKlotho-FGF receptor complex formation, methods of causing increased FGF21 receptor agonist-βKlotho-FGF receptor complex formation, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
Owner:NEW YORK UNIV
Inhibitors of the fibroblast growth factor receptor
Described herein are inhibitors of FGFR, pharmaceutical compositions including such compounds, and methods of using such compounds and compositions to inhibit the activity of tyrosine kinases.
Owner:BLUEPRINT MEDICINES
Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
InactiveUS6878383B2Promote tissue regenerationPrevent emergenceBiocideImpression capsDiseaseFibroblast
The invention provides a composition for promoting regeneration of tissue which has degenerated in a subject as a result of a disease or disorder and a method of using the composition is provided. The composition comprises a biodegradable acellular matrix, and passaged autologous fibroblasts substantially free of immunogenic proteins, e.g., culture medium serum-derived proteins, integrated within the matrix. Also provided is an injectable composition comprising an acellular filler material (e.g., any type of collagen) and passaged autologous fibroblasts substantially free of immunogenic proteins, e.g., culture medium serum-derived proteins, for correcting defects in skin, such as wrinkles or scars, and for augmenting tissue in the subject, particularly facial tissue.
Owner:CASTLE CREEK BIOSCIENCES LLC
Compositions comprising variants and fusions of FGF19 polypeptides, and uses and methods thereof for treatment of metabolic disorders and diseases
ActiveUS8951966B2Lower Level RequirementsIncrease insulin sensitivityOrganic active ingredientsBacteriaDiseaseFGF19
The invention relates to variants and fusions of fibroblast growth factor 19 (FGF19), variants and fusions of fibroblast growth factor 21 (FGF21), fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21), and variants or fusions of fibroblast growth factor 19 (FGF19) and / or fibroblast growth factor 21 (FGF21) proteins and peptide sequences (and peptidomimetics), having one or more activities, such as glucose lowering activity, and methods for and uses in treatment of hyperglycemia and other disorders.
Owner:NGM BIOPHARMLS
Methods and devices for differentiating pluripotent stem cells into cells of the pancreatic lineage
Methods and devices for culturing human pluripotent stem cells to produce cells of the pancreatic lineage are disclosed. The methods include steps of culturing the stem cells under conditions that induce the expression of mesendoderm / primitive streak and definitive endoderm markers in a chemically defined medium including an effective amount of i) fibroblast growth factor, ii) Activin A, and iii) bone morphogenetic protein. The methods further include the steps of culturing cells under conditions favoring the formation of at least one of intact embryoid bodies and pancreatic progenitor PDX1+ Ins− cells.
Owner:WISCONSIN ALUMNI RES FOUND
FAP-activated anti-tumor compounds
The invention relates to a prodrug that is capable of being converted into a drug by the catalytic action of human fibroblast activation protein (FAPalpha), said prodrug having a cleavage site which is recognised by FAPalpha, and said drug being cytotoxic or cytostatic under physiological conditions.
Owner:BOEHRINGER INGELHEIM PHARM KG
Tissue-like organization of cells and macroscopic tissue-like constructs, generated by macromass culture of cells, and the method of macromass culture
InactiveUS20040082063A1Sectioned easilySmall sizeEpidermal cells/skin cellsMammal material medical ingredientsHigh cellFiber
Three-dimensional tissue-like organization of cells by high cell-seeding-density culture termed as macromass culture is described. By macromass culture, cells can be made to organize themselves into a tissue-like form without the aid of a scaffold and three-dimensional macroscopic tissue-like constructs can be made wholly from cells. Tissue-like organization and macroscopic tissue-like constructs can be generated from fibroblastic cells of mesenchymal origin (at least), which can be either differentiated cells or multipotent adult stem cells. In this work, tissue-like organization and macroscopic tissue-like constructs have been generated from dermal fibroblasts, adipose stromal cells-derived osteogenic cells, chondrocytes, and from osteoblasts. The factor causing macroscopic tissue formation is large scale culture at high cell seeding density per unit area or three-dimensional space, that is, macromass culture done on a large scale. No scaffold or extraneous matrix is used for tissue generation, the tissues are of completely cellular origin. No other agents (except high cell-seeding-density) that aid in tissue formation such as tissue-inducing chemicals, tissue-inducing growth factors, substratum with special properties, rotational culture, etc, are employed for tissue formation. These tissue-like masses have the potential for use as tissue replacements in the human body. Tissue-like organization by high cell-seeding-density macromass culture can also be generated at the microscopic level.
Owner:RELIANCE LIFE SCI PVT
Method and composition for restoration of age related tissue loss in the face or selected areas of the body
InactiveUS20060073178A1Restoring age related tissue lossEasy to produceCosmetic preparationsBiocideInsulin-like growth factorThyroid hormones
A treatment method for restoring of age related tissue loss in the face or selected areas of the body is disclosed which includes injecting an injectable composition containing a growth factor and hyaluronic acid as a carrier into the dermis, the hypodermis, or both, in various areas of the face, or selected areas of the body of a person to stimulate collagen, elastin, or fat cell production, thereby restoring age related tissue loss in the face and selected areas of the body. Further disclosed is an injectable composition for restoring of age related tissue loss in the face and selected areas of the body, which contains a growth factor and hyaluronic acid as a carrier for providing time release of the growth factor into tissues. The growth factor can be insulin, insulin-like growth factor, thyroid hormone, fibroblast growth factor, estrogen, retinoic acid, or their combinations.
Owner:CELLHEALTH TECH
Overexpression porcine co-stimulatory 4-1BB vector and application thereof
InactiveCN105087620AHigh copy numberLower activation thresholdVector-based foreign material introductionAnimal husbandryInteinEmbryo
The invention provides an overexpression porcine co-stimulatory 4-1BB vector and application thereof. PCR (polymerase chain reaction) amplification is performed on a left homologous arm and a right homologous arm of an intron 1 of a rosa26 gene, a 4-1BB regulatory sequence and an OCT4 specific promoter; the left homologous arm, a 4-1BB expression cassette, LoxP locus-contained Cre and Neo expression cassettes, the right homologous arm and negative selection DTA diphtheria toxin are connected in sequence to obtain a 4-1BB homologous recombinant vector p4BOCNDR; the vector and a CRISPR / Cas9 (clustered regularly interspaced short palindromic repeats / CRISPR-associated) targeting vector of sgRNA (small guide ribonucleic acid) containing the intron 1 of the specific targeting porcine rosa26 gene are transferred together into a porcine fetus fibroblast; by taking a positive cell as a donor cell and an oocyte as a recipient cell, a cloned embryo is obtained through a somatic cell nuclear transfer technique; the cloned embryo is transplanted into a porcine uterus for fetation to obtain a transgenic pig integrating a 4-1BB gene at the fixed point of a first intron of the rosa26 gene and automatically deleting a marker gene.
Owner:CHINA AGRI UNIV
Graft materials containing ECM components, and methods for their manufacture
ActiveUS20080107750A1Peptide/protein ingredientsMammal material medical ingredientsCell-Extracellular MatrixECM Protein
Described are packaged, sterile medical graft products containing controlled levels of a growth factor such as Fibroblast Growth Factor-2 (FGF-2). Also described are methods of manufacturing medical graft products wherein processing, including sterilization, is controlled and monitored to provide medical graft products having modulated, known levels of a extracellular matrix factor, such as a growth factor, e.g. FGF-2. Preferred graft materials are extracellular matrix materials isolated from human or animal donors, particularly submucosa-containing extracellular matrix materials. Further described are ECM compositions that are or are useful for preparing gels, and related methods for preparation and use.
Owner:COOK BIOTECH +1
Muteins of fibroblast growth factor 21
InactiveUS20090118190A1Antibacterial agentsPeptide/protein ingredientsCritically illNucleic acid sequencing
The present invention relates to novel muteins of human fibroblast growth factor 21 with improved pharmaceutical properties. Both protein and the respective encoding nucleic acid species are disclosed. The invention also embodies vectors and host cells for the propagation of said nucleic acid sequences and the production of said muteins. Also disclosed are methods for treating type 2 diabetes, obesity, metabolic syndrome, and in reducing the mortality and morbidity of critically ill patients.
Owner:BEALS JOHN MICHAEL +7
Anti-wrinkle composition
ActiveUS20070166267A1Easy to superviseAccurate balanceBiocideOrganic active ingredientsWrinkle skinDimethyl isosorbide
A composition is disclosed for treating the skin comprising an acylated short chain bioactive peptide and Lycium barbarum extract product. Also disclosed is a method for topically administering the composition in an amount therapeutically effective to reduce wrinkles by building the dermal fibroblast matrix. The composition may contain dimethylisosorbide or ethoxydiglycol as solubilizing and penetration enhancers for the hydrophobically modified peptide.
Owner:GRANT INDS
Chimeric fibroblast growth factor 19 proteins and methods of use
ActiveUS20130331317A1Enhanced endocrine activityLow affinityPeptide/protein ingredientsAntibody mimetics/scaffoldsKlothoHeparin-DHE
The present invention relates to a chimeric protein that includes an N-terminus coupled to a C-terminus, where the N-terminus includes a portion of a paracrine fibroblast growth factor (“FGF”) and the C-terminus includes a C-terminal portion of an FGF19 molecule. The portion of the paracrine FGF is modified to decrease binding affinity for heparin and / or heparan sulfate compared to the portion without the modification. The present invention also relates to pharmaceutical compositions including chimeric proteins according to the present invention, methods for treating a subject suffering from diabetes, obesity, or metabolic syndrome, and methods of screening for compounds with enhanced binding affinity for the βKlotho-FGF receptor complex involving the use of chimeric proteins of the present invention.
Owner:SALK INST FOR BIOLOGICAL STUDIES +2
Differentiation modulating agents and uses therefor
InactiveUS20120059047A1Reduce expressionIncrease gene expressionOrganic active ingredientsPeptide/protein ingredientsSignalling pathwaysObesity
The present invention is directed to methods and agents for modulating the differentiation potential and / or proliferation of preadipocytes. More particularly, the present invention discloses methods and agents for modulating a fibroblast growth factor (FGF) signaling pathway, especially the FGF-1 or FGF-2 signaling pathway, for treating or preventing adiposity-related conditions including, but not limited to, obesity, lipoma, lipomatosis, cachexia or lipodystrophy or the loss of adipose tissue in trauma or atrophic conditions.
Owner:VERVA PHARMA
Compositions And Methods For Preventing Or Treating Diseases, Conditions, Or Processes Characterized By Aberrant Fibroblast Proliferation And Extracellular Matrix Deposition
InactiveUS20120263680A1Good adhesionPeptide/protein ingredientsAntibody ingredientsDiseaseCell-Extracellular Matrix
The described invention provides compositions and methods for preventing or treating a disease, condition, or pathologic process characterized by aberrant fibroblast proliferation and extracellular matrix deposition in a tissue of a subject. The method includes administering a therapeutic amount of a pharmaceutical composition comprising a polypeptide having the amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or functional equivalent thereof, and a pharmaceutically acceptable carrier.
Owner:MOERAE MATRIX
Conjoint therapy for treating fibrotic diseases
ActiveUS20100111898A1Inhibition of activationReduce inhibitionAntibacterial agentsOrganic active ingredientsDiseaseCombined Modality Therapy
The present invention relates to improved methods of treating fibrotic or fibroproliferative disorders. Conjoint therapies are provided comprising the combination of one or more fibrocyte suppressors and one or more profibrotic factor antagonists or anti-fibrotic agents.
Owner:PROMEDIOR
Features
- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
Why Patsnap Eureka
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com